CL2019003515A1 - Compuestos heteroaromáticos como inhibidores de vanina. - Google Patents
Compuestos heteroaromáticos como inhibidores de vanina.Info
- Publication number
- CL2019003515A1 CL2019003515A1 CL2019003515A CL2019003515A CL2019003515A1 CL 2019003515 A1 CL2019003515 A1 CL 2019003515A1 CL 2019003515 A CL2019003515 A CL 2019003515A CL 2019003515 A CL2019003515 A CL 2019003515A CL 2019003515 A1 CL2019003515 A1 CL 2019003515A1
- Authority
- CL
- Chile
- Prior art keywords
- heteroaromatic compounds
- compounds
- vanin
- inhibitors
- vanin inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
LA PRESENTE INVENCIÓN ABARCA LOS COMPUESTOS DE LA FÓRMULA (I), EN DONDE LOS GRUPOS A Y B SE DEFINEN EN LA PRESENTE, QUE SON ADECUADOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON VANINA, Y LOS PROCESOS PARA FABRICAR ESTOS COMPUESTOS, LAS PREPARACIONES FARMACÉUTICAS QUE CONTIENEN ESTOS COMPUESTOS Y SUS MÉTODOS DE USO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518106P | 2017-06-12 | 2017-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003515A1 true CL2019003515A1 (es) | 2020-06-19 |
Family
ID=62631060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003515A CL2019003515A1 (es) | 2017-06-12 | 2019-12-02 | Compuestos heteroaromáticos como inhibidores de vanina. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10364255B2 (es) |
| EP (1) | EP3638680B1 (es) |
| JP (1) | JP6880243B2 (es) |
| KR (1) | KR102607934B1 (es) |
| CN (1) | CN110770242B (es) |
| AR (1) | AR112086A1 (es) |
| AU (1) | AU2018285131B2 (es) |
| BR (1) | BR112019021703A2 (es) |
| CA (1) | CA3066946A1 (es) |
| CL (1) | CL2019003515A1 (es) |
| CO (1) | CO2019013823A2 (es) |
| DK (1) | DK3638680T3 (es) |
| EA (1) | EA039223B1 (es) |
| ES (1) | ES2927021T3 (es) |
| HU (1) | HUE060597T2 (es) |
| IL (1) | IL271104B (es) |
| MA (1) | MA49374A (es) |
| MX (1) | MX2019014876A (es) |
| PE (1) | PE20200340A1 (es) |
| PH (1) | PH12019502693A1 (es) |
| PL (1) | PL3638680T3 (es) |
| TW (1) | TWI855993B (es) |
| WO (1) | WO2018228934A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018285131B2 (en) * | 2017-06-12 | 2021-11-11 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
| PL3837263T3 (pl) | 2018-08-13 | 2024-10-14 | F. Hoffmann-La Roche Ag | Nowe związki heterocykliczne jako inhibitory lipazy monoacyloglicerolowej |
| MA53479A (fr) * | 2018-08-28 | 2022-05-04 | Boehringer Ingelheim Int | Composés hétérocycliques en tant q'inibiteurs de vanin |
| MA54378A (fr) | 2018-12-03 | 2022-03-09 | Boehringer Ingelheim Int | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine |
| CN114269755A (zh) | 2019-09-12 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物 |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE419242T1 (de) * | 2003-10-09 | 2009-01-15 | Abbott Lab | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren |
| CA2987179C (en) * | 2015-05-29 | 2020-08-25 | Pfizer Inc. | Heterocyclic compounds as inhibitors of vanin-1 enzyme |
| JP2019524716A (ja) * | 2016-07-14 | 2019-09-05 | ファイザー・インク | バニン１酵素の阻害薬としての新規のピリミジンカルボキサミド |
| AU2018285131B2 (en) * | 2017-06-12 | 2021-11-11 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
-
2018
- 2018-06-08 AU AU2018285131A patent/AU2018285131B2/en active Active
- 2018-06-08 CN CN201880039562.3A patent/CN110770242B/zh active Active
- 2018-06-08 PE PE2019002531A patent/PE20200340A1/es unknown
- 2018-06-08 WO PCT/EP2018/065140 patent/WO2018228934A1/en active Application Filing
- 2018-06-08 JP JP2019566724A patent/JP6880243B2/ja active Active
- 2018-06-08 PL PL18731766.4T patent/PL3638680T3/pl unknown
- 2018-06-08 US US16/003,252 patent/US10364255B2/en active Active
- 2018-06-08 DK DK18731766.4T patent/DK3638680T3/da active
- 2018-06-08 KR KR1020197038628A patent/KR102607934B1/ko active IP Right Grant
- 2018-06-08 EA EA202090014A patent/EA039223B1/ru unknown
- 2018-06-08 ES ES18731766T patent/ES2927021T3/es active Active
- 2018-06-08 MX MX2019014876A patent/MX2019014876A/es unknown
- 2018-06-08 EP EP18731766.4A patent/EP3638680B1/en active Active
- 2018-06-08 CA CA3066946A patent/CA3066946A1/en active Pending
- 2018-06-08 HU HUE18731766A patent/HUE060597T2/hu unknown
- 2018-06-08 BR BR112019021703-7A patent/BR112019021703A2/pt unknown
- 2018-06-08 MA MA049374A patent/MA49374A/fr unknown
- 2018-06-11 AR ARP180101573A patent/AR112086A1/es unknown
- 2018-06-11 TW TW107119946A patent/TWI855993B/zh active
-
2019
- 2019-05-13 US US16/410,037 patent/US20190263828A1/en not_active Abandoned
- 2019-11-28 PH PH12019502693A patent/PH12019502693A1/en unknown
- 2019-12-02 IL IL271104A patent/IL271104B/en unknown
- 2019-12-02 CL CL2019003515A patent/CL2019003515A1/es unknown
- 2019-12-09 CO CONC2019/0013823A patent/CO2019013823A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180354968A1 (en) | 2018-12-13 |
| MA49374A (fr) | 2021-04-21 |
| PH12019502693A1 (en) | 2020-07-13 |
| CA3066946A1 (en) | 2018-12-20 |
| IL271104B (en) | 2022-03-01 |
| JP2020522517A (ja) | 2020-07-30 |
| CO2019013823A2 (es) | 2020-01-17 |
| ES2927021T3 (es) | 2022-11-02 |
| AR112086A1 (es) | 2019-09-18 |
| IL271104A (en) | 2020-01-30 |
| PL3638680T3 (pl) | 2022-12-19 |
| EA202090014A1 (ru) | 2020-05-12 |
| US20190263828A1 (en) | 2019-08-29 |
| KR102607934B1 (ko) | 2023-12-01 |
| HUE060597T2 (hu) | 2023-04-28 |
| CN110770242B (zh) | 2022-08-19 |
| AU2018285131A1 (en) | 2019-10-31 |
| EP3638680B1 (en) | 2022-08-10 |
| BR112019021703A2 (pt) | 2020-05-12 |
| EA039223B1 (ru) | 2021-12-20 |
| JP6880243B2 (ja) | 2021-06-02 |
| US10364255B2 (en) | 2019-07-30 |
| MX2019014876A (es) | 2020-02-13 |
| PE20200340A1 (es) | 2020-02-14 |
| TWI855993B (zh) | 2024-09-21 |
| DK3638680T3 (da) | 2022-09-05 |
| EP3638680A1 (en) | 2020-04-22 |
| KR20200013718A (ko) | 2020-02-07 |
| AU2018285131B2 (en) | 2021-11-11 |
| TW201920196A (zh) | 2019-06-01 |
| CN110770242A (zh) | 2020-02-07 |
| WO2018228934A1 (en) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018005954A2 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| ECSP15008851A (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| CO2017011484A2 (es) | Inhibidores de bromodominio | |
| CL2019003515A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina. | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| CO2021007173A2 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| NI201700096A (es) | Derivados de 4h-pirrol[3, 2-c]piridin-4-ona | |
| UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| CO2021002225A2 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CO2019013016A2 (es) | Inhibidores pirazólicos de magl | |
| UY36737A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| MX2021006489A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| CO2019006687A2 (es) | Polimorfos | |
| CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
| ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
| CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores |